Anti–Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper

Biologic therapy with anti–tumor necrosis factor (TNF)-α antibody medications has become part of the standard of care for medical therapy for patients with inflammatory bowel disease and may help to avoid surgery in some. However, many of these patients will still require surgical intervention in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Holubar, Stefan D., Holder-Murray, Jennifer, Flasar, Mark, Lazarev, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
CCFA Position Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623843/
https://www.ncbi.nlm.nih.gov/pubmed/26422516
http://dx.doi.org/10.1097/MIB.0000000000000603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623843/
https://www.ncbi.nlm.nih.gov/pubmed/26422516
http://dx.doi.org/10.1097/MIB.0000000000000603

Ejemplares similares